日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease

缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他(一种治疗慢性肾病贫血的新方法)的非临床表征

Ughetta Del Balzo, Pierre E Signore, Gail Walkinshaw, Todd W Seeley, Mitchell C Brenner, Qingjian Wang, Guangjie Guo, Michael P Arend, Lee A Flippin, F Aisha Chow, David C Gervasi, Christian H Kjaergaard, Ingrid Langsetmo, Volkmar Guenzler, David Y Liu, Steve J Klaus, Al Lin, Thomas B Neff

Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients

口服缺氧诱导因子脯氨酰羟化酶抑制剂罗沙司他(FG-4592)治疗慢性肾病贫血:血液透析患者药代动力学和药效学安慰剂对照研究

Robert Provenzano, James Tumlin, Raja Zabaneh, James Chou, Stefan Hemmerich, Thomas B Neff, K-H Peony Yu

Induction of erythropoiesis by hypoxia-inducible factor prolyl hydroxylase inhibitors without promotion of tumor initiation, progression, or metastasis in a VEGF-sensitive model of spontaneous breast cancer

在 VEGF 敏感的自发性乳腺癌模型中,缺氧诱导因子脯氨酰羟化酶抑制剂可诱导红细胞生成,且不会促进肿瘤发生、进展或转移

Todd W Seeley, Mark D Sternlicht, Stephen J Klaus, Thomas B Neff, David Y Liu